Nextgen Cash Flow Conversion Efficiency
Nextgen cash flow conversion efficiency. Based on the latest financial reports, Nextgen (NXGN) has a cash flow conversion efficiency ratio of 0.111x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-1.08 Million ≈ $-2.90K USD) by net assets (ILA-9.72 Million ≈ $-26.05K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nextgen (2013–2024)
Cash flow conversion efficiency of Nextgen from 2013 to 2024. This chart illustrates how Nextgen's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Nextgen stock price today for real-time trading data and today's change.
Nextgen Cash Flow Conversion Ratio Explained
Nextgen cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nextgen Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nextgen ranked by their cash flow conversion efficiency. Also see Nextgen (NXGN) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MUZHU MINING LTD
F:Y33
|
N/A |
|
Vault Strategic Mining Corp.
V:KNOX
|
-1.008x |
|
Astron Paper & Board Mill Limited
NSE:ASTRON
|
0.079x |
|
Foxtons Group Plc
LSE:FOXT
|
0.054x |
|
Gabather AB (publ)
ST:GABA
|
-0.117x |
|
Vanquis Banking Group PLC
LSE:VANQ
|
0.406x |
|
Quartix Holdings Plc
LSE:QTX
|
0.121x |
|
Link Bilgisayar Sistemleri Yazilimi ve Donanimi Sanayi ve Ticaret AS
IS:LINK
|
0.021x |
Annual Cash Flow Conversion Efficiency for Nextgen (2013–2024)
The table below shows the annual cash flow conversion efficiency of Nextgen from 2013 to 2024. Review NXGN FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA-2.46 Million ≈ $-6.61K |
ILA-2.06 Million ≈ $-5.53K |
0.837x | -81.41% |
| 2023-12-31 | ILA-979.00K ≈ $-2.62K |
ILA-4.41 Million ≈ $-11.81K |
4.499x | +2102.13% |
| 2022-12-31 | ILA12.25 Million ≈ $32.84K |
ILA-2.75 Million ≈ $-7.38K |
-0.225x | -75.07% |
| 2021-12-31 | ILA20.71 Million ≈ $55.51K |
ILA-2.66 Million ≈ $-7.13K |
-0.128x | +42.64% |
| 2020-12-31 | ILA6.87 Million ≈ $18.41K |
ILA-1.54 Million ≈ $-4.12K |
-0.224x | +77.11% |
| 2019-12-31 | ILA1.17 Million ≈ $3.14K |
ILA-1.15 Million ≈ $-3.07K |
-0.978x | -88.16% |
| 2018-12-31 | ILA2.39 Million ≈ $6.40K |
ILA-1.24 Million ≈ $-3.33K |
-0.520x | -14.45% |
| 2017-12-31 | ILA3.66 Million ≈ $9.81K |
ILA-1.66 Million ≈ $-4.45K |
-0.454x | -54.05% |
| 2016-12-31 | ILA5.13 Million ≈ $13.76K |
ILA-1.51 Million ≈ $-4.06K |
-0.295x | +87.25% |
| 2015-12-31 | ILA1.74 Million ≈ $4.65K |
ILA-4.01 Million ≈ $-10.76K |
-2.312x | -162.46% |
| 2014-12-31 | ILA-884.00K ≈ $-2.37K |
ILA-3.27 Million ≈ $-8.77K |
3.702x | +205.08% |
| 2013-12-31 | ILA342.00K ≈ $916.89 |
ILA-1.21 Million ≈ $-3.23K |
-3.523x | -- |
About Nextgen
Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.